An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 08 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 03 Aug 2015 Planned End Date changed from 1 Oct 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.